Since some tests have become more common to offer in routine laboratories, we as a specialist laboratory have decided to remove tests that cannot be regarded as specialist tests any longer or tests have been removed from our portfolio since research has shown that these no longer give any added diagnostic value.
We have the pleasure to inform about the following new tests and updates in our portfolio:
Please note that we have changed the order of the panels on the Request Form.
New Complement Activity Marker: C4d – (No. 911)
In several autoimmune diseases (SLE, Systemic sclerosis, ANCA vasculitis), an elevated plasma C4d can be linked to disease activity and kidney-affected flares. Also, in lung cancer, elevated C4d has been shown to be able to differentiate patients with intermediate nodules and in malignant pleural mesothelioma correlate with tumor volume and chemotherapy response. C4d is a specific biomarker for activity in the complementary system's classic pathway and lectin pathway.
New Panel for Extended Analysis for Suspected Anti-Phospholipid Syndrome (Panel 579)
Anti-Cardiolipin (IgA) No. 017, Anti-Beta-2 Glycoprotein (IgA) No. 146 & Anti-Phosphatidylserine (IgGAM) No. 403 (screening).
New Panel for Primary Membranous Nephropathy (PMN) - (panel 584)
Anti-PLA2R and Anti-THSD7A Screening. For follow-up of positive results for PLA2R, an anti-PLA2R (ELISA) No. 247 is offered.
New panel for expanded analysis - suspected autoimmune hepatitis (panel 018)
Liver screen (anti-LKM-1, LC-1, AMA-M2, M2-3E (BPO). Sp100, PML, gp210, SLA / LP & Ro-52). Can only be ordered as a panel. This means that anti-SLA / LP is no longer included in panel 515.
New panel for expanded analysis - suspected autoantibodies in Autoimmune pancreatitis type 2 (AIP2), (panel 575).
Anti-Carboanhydrase II No. 850, anti-Lactoferrin (DNA bound) No. 859, anti-Thyreoglobulin No. 865 and IIF ANCA (p-ANCA).
New subclass determination of specific IgG for GBM (IgG1-4), no. 100 and GBM (IgG4), (no. 145).
An additional test for the GBM assay.
Panel no. 501; Suspected systemic vasculitis & anti-GBM disease. A test for ds-DNA has been added.
Panel 520 - connective tissue disease – undifferentiated
The IIF-ANCA test has been removed from the panel.
Panel 530 Sudden deafness
IIF-ANCA and anti-cardiolipin have been removed from the panel and PR3-ANCA has been added.
Panel 512 - when investigating for Celiac disease, test for anti-transglutaminase (IgA) and IgA quantification will primarily be performed
If IgA deficiency is detected, analysis for Transglutaminase IgG and Deamidated Gliadin IgG is further performed.
Panel 578 - when investigating for Celiac disease in children, an expanded analysis is offered - tests for anti-Endomysium IgA and Deamidated Gliadin IgA
When testing for Gangliosides (GM1, GM2, Gd1a, Gd1b and Gq1b) - serum should always be used as sample material in the first place.
No TDM samples need to be sent frozen any longer. They should be sent at room temperature or cooled (between cold packs). This is clearly stated on the Request Forms for each drug.
092 anti-skin IIF has been removed from the portfolio and thus also from panel no. 550.
008 IIF-ANCA is no longer included in panel 503 or 530 but remains in panels 541 and 575.
On September 1, 2018, our parent company changed its name from Euro Diagnostica to Svar Life Science AB.
For Wieslab's part, this means that we have a new logotype, new address for our website www.svarlifescience.com, new email addresses (firstname.lastname@svarlifescience).
We are still in our premises in Malmö so there has been no change in terms of address or telephone numbers.
Our Request Forms have been updated with the above changes and have new color coding: Autoimmune Diagnostics are clear blue (previously red), Neurology is gray (formerly light purple) and Monitoring of Biological Drugs is black (formerly dark blue). This means that the sample material that we receive will be analyzed according to the content of the updated Request Forms even if the sample material is sent together with an "old" Request Forms.
Can be ordered via email to Diagnostic.email@example.com
You can also contact Sr Key Account Manager, Monica Blixt: firstname.lastname@example.org
In January 2019, we will implement @invoicing. This means that we will not send any paper invoices if you as customers do not specifically request it. For this to work as well as possible, it is important that you provide the correct reference code/cost center on the Request Forms.
FOR MORE INFORMATION, PLEASE CONTACT:
Lab Manager, Rita Martins Olofsson: 040 - 643 44 12,
Key Account Manager, Monica Blixt: 0708 - 86 28 10,
Laboratory: 040 - 53 76 60